CEL-SCI Corporation Chief Scientific Officer to the data on the support of innovative treatments for cancer vaccine of World Congress on April 14th

Current article ratings:
Patients / public:healthcare Prof:5 (1 votes)
CEL-SCI Corporation (NYSE AMEX: CVM) today announced that Eyal Talor, PhD., Chief Scientific Officer, a presentation titled "Jumps peptide and protein vaccines and protein ® immunotherapy for cancer" on April 14th in the world vaccine Congress 2011 at 2:50 am to the Gaylord of national hotel & Convention Center-Washington DC. The Conference gathered together North America leading Government, business and scientific leaders as they continue the scientific and strategic innovation behind the emerging vaccine industry to improve.

Dr. Talor discuss the next generation of cancer vaccines, including protein immune therapy, which offer a new approach to the vaccine and that some of the might be able to overcome difficulties due to the currently used and more traditional cancer vaccines. This new approach in the design and development of cancer vaccines and treatment relies not on the need to isolate of autologous (patient own) tumor antigens for the production of these vaccines and treatments, and possibly also to resist tumor mutations and tumour mechanisms, on the inhibition of an effective anti-tumor response directed are overcome in cancer patients.

Dr. Talor discussion contains a summary of the Leukocyte's results in phase I / II and provides information about the design of the phase III study currently in progress. The presentation describes also the cracks as peptide technology which is developed as a technology platform for vaccines, including applications in areas of vaccines, rheumatoid arthritis, HSV, H1N1 and cancer. Dr. Talor also provides an update on the work that does the company in the development of dendritic vaccines for other emerging viral diseases.

Source:
CEL-SCI Corporation